产品说明书

Acelarin

Print
Chemical Structure| 840506-29-8 同义名 : NUC-1031;CPF-31;GTPL7389;MTL-007
CAS号 : 840506-29-8
货号 : A426804
分子式 : C25H27F2N4O8P
纯度 : 99%+
分子量 : 580.475
MDL号 : MFCD27987942
存储条件:

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 35 mg/mL(60.3 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
靶点
  • DNA synthesis

    DNA synthesis, EC50:0.2 nM

描述 Gemcitabine is a pyrimidine nucleoside analogue commonly used for the treatment of solid tumors. Acelarin is a gemcitabine ProTide with cytotoxic activity against a range of cancer cell lines in vitro, including L1210 (IC50=0.035±0.02μM), CEM (IC50=0.1±0.03μM), MP-2 (IC50=0.44±0.06μM), and BxPC-3 (IC50=0.15±0.04μM). The colorimetric MTT assay showed that acelarin was more cytotoxic than gemcitabine and its activity was not significantly affected by deoxycytidine. In a nude mouse xenograft model of MiaPaCa-2 human pancreatic cancer cells, acelarin at a dose of 0.076mmol/kg achieved significantly greater reduction in tumor volume than gemcitabine on Day 7 after the first administration of the compounds[2].
作用机制 Acelarin is a gemcitabine ProTide that bears a phosphoramidate moiety on the 5’-carbon of the ribose. It has been shown to resist cytidine deaminase-mediated degradation. Acelarin bypasses deoxycytidine kinase-mediated monophosphorylation and does not rely on the nucleoside transporter human equilibrative nucleoside transporter-1 to exert the anticancer effect.[2]
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.61mL

1.72mL

0.86mL

17.23mL

3.45mL

1.72mL

参考文献

[1]Slusarczyk M, Lopez MH, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014 Feb 27;57(4):1531-42.

[2]Slusarczyk M, Lopez MH, Balzarini J, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014;57(4):1531-1542